Jun 07, 2012
61 Health Benefits of Omega-3 Fatty Acids
Health Benefits of Omega-3 Fatty Acids
Pat Robinson
5 minSearch Research
Search across 105,000+ research abstracts, articles, substances, health topics, keywords, and actions.
Found 15 results for "Omega-3"
Articles (6)
View all
Jun 12, 2012
Omega-3 and Vascular Disease
Omega-3 in modest doses reduces cardiac deaths , and in high doses reduces nonfatal cardiovascular
Pat Robinson
3 min
Jan 09, 2013
Are Statin Drugs Killing the Health Benefits of Omega-3 Fat?
with the heart-protective effects of omega-3 fatty acids in those who are taking them
Sayer Ji
5 min
Jan 28, 2021
Most Comprehensive Study to Date: Omega-3 Reduces Heart Risks
omega-3 fats for heart health. If fatty fish is not a regular part of your
GMI Research Group
4 min
Nov 19, 2013
Omega-3 Fats Help Overcome Multi-Drug Resistant Cancer
omega-3 fatty acids may combat the most fearsome disease known to humankind: multi-drug
Sayer Ji
4 minAbstracts (6)
View allOmega-3 fatty acid intake and circadian syndrome in U.S. adults
Circadian Syndrome (CircS) appears to be a better predictor for cardiovascular disease than Metabolic Syndrome (MetS), and omega-3 fatty acids (omega-3) are generally suggested to alleviate negative health outcomes. This study aims to investigate the association between omega-3 intake and CircS, and examine effect modification by sociodemographic and lifestyle factors.In this cross-sectional study, data from the National Health and Nutrition Examination Survey (NHANES) 2005-2018 were analyzed (n=12,028). Survey-weighted multivariable logistic regression was applied to analyze the associations of omega-3 intake with CircS and its components. Subgroup analyses examining the effect modification by sociodemographic and lifestyle factors were followed by a Restricted Cubic Spline investigating the nonlinear associations between omega-3 intake and CircS by race.The weighted prevalence of MetS and CircS was 45.8% and 37.3%, respectively. Overall, no significant associations were found between the intake of total omega-3, Eicosapentaenoic Acid (EPA), or Docosahexaenoic Acid (DHA) and CircS. However, omega-3 intake was associated with a lower risk of depression- a component of CircS. Comparing extreme quartiles of omega-3 intake (highest vs lowest), the OR (95% CI) for depressive symptoms was 0.77 (0.64-0.90). Among the Black, those in the highest quartile of omega-3 intake were more likely to have CircS, with the OR (95% CI) of 1.36 (1.02-1.82).No association between omega-3 intake and CircS in the total study population was observed. However, Omega-3 intake was inversely associated with depressive symptoms in American adults. Interactions between race and omega-3 intake in relation to CircS were also identified.
Dan Zhang, Dandan Sun, Bizhong Che, Bin Zhang, Lei Zhao, Youfa Wang, Zumin Shi, Wen Peng, Br J Nutr
Human Study
Vitamin D and Omega-3 Supplementation for Emotional and Behavioral Dysregulation in Autism Spectrum Disorders: A Systematic Review.
Emotional dysregulation (ED) is emerging as a major contributor to functional impairment in Autism Spectrum Disorder (ASD). Although effective behavioral interventions exist, pharmacological treatments remain constrained by side effects and variable tolerability. Given their neurobiological roles that include neurotransmission, inflammation, and neuroplasticity, vitamin D and omega-3 polyunsaturated fatty acids (PUFAs) have been identified as promising candidates for modulating emotional and behavioral dysregulation. This systematic review aimed to evaluate the efficacy of combined vitamin D and omega-3 supplementation in improving emotional and behavioral regulation in individuals with ASD. This review was conducted in accordance with PRISMA guidelines. Included studies were English peer-reviewed studies involving participants with ASD that assessed combined vitamin D and omega-3 suppleupplementation with outcomes related to emotional or behavioral dysregulation. The search was restricted to 2015-2025 to ensure inclusion of recent, methodologically consistent studies and to minimize heterogeneity in diagnostic criteria and supplementation protocols. Of 649 records initially screened, 3 studies met inclusion criteria: one randomized controlled trial, one observational study, and one case report, involving participants ranging from early childhood to young adulthood. Across studies, combined supplementation was associated with improvements in irritability, hyperactivity, agitation, and self-injurious behaviors. These clinical effects were accompanied by specific biochemical changes, including reductions in the AA/EPA ratio, increases in serum 25(OH)D and omega-3 indices, and decreased urinary levels of HVA and VMA. This review indicates that co-supplementation with vitamin D and omega-3 fatty acids may exert preliminary beneficial effects on emotional and behavioral dysregulation in individuals with ASD, potentially through anti-inflammatory and neuroregulatory mechanisms. However, the available evidence remains limited due to a small number of studies, their modest sample size, and methodological heterogeneity. Further, biomarker-driven randomized studies are needed to confirm efficacy and delineate optimal dosing strategies for application in clinics.
Berni M, Mutti G, Tancredi R, Muratori F, Calderoni S, Journal of clinical medicine
The effectiveness of intervention with omega-3 fatty acids, eicosapentaenoic and docosahexenoic acid in peripheral arterial disease: a systematic review and meta-analysis.
AIMS: Omega-3 polyunsaturated fatty acids are routinely recommended as a lifestyle modification for preventing cardiovascular disease (CVD). It is not clear if any omega-3 polyunsaturated fatty acid formulations are favourable for patients with peripheral artery disease (PAD). DATA SYNTHESIS: A systematic review and meta-analysis (PROSPERO registration ID CRD42022336641) was conducted to determine the effects of omega-3 fatty acids on functional outcomes in people with PAD. Studies reporting any dose of eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) supplementation versus placebo were assessed by two independent reviewers. Data including study design, number, age and sex of participants, period of assessment, diagnosis method for PAD, inclusion and exclusion criteria, method and formulation of omega-3 supplementation were analysed. Risk of bias was determined using the Newcastle-Ottawa scale. Of 1067 citations, 12 studies (n = 759 patients) met the predefined inclusion criteria. Supplementation of EPA, or EPA + DHA did not alter the primary outcome measures of pain-free walking distance, maximal walking distance; ankle brachial index, or flow mediated vasodilation versus placebo. There were no changes in secondary outcomes of circulating inflammatory markers, cholesterol, or blood pressure. CONCLUSION: Mixed omega-3 fatty acids, especially in low doses, are not effective in reducing symptoms of PAD. However, there is insufficient evidence to rule out effectiveness of specific omega 3 formulations, particularly for high-risk populations. Therefore, it is recommended that a large scale, randomised control trial with high dose EPA is conducted in patients with PAD.
Dao TK, Nerlekar N, Nicholls SJ, Bubb KJ, Nutrition, metabolism, and cardiovascular diseases : NMCD
[High-dose omega-3 fatty acid supplementation in patients with persistent allergic rhinitis sensitized to perennial allergens: a randomized, placebo-controlled clinical trial].
OBJECTIVE: To evaluate the effect of high-dose eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on the severity of allergic rhinitis and the quality of life of patients affected by this condition. METHODS: Randomized, double-blind, placebo-controlled study. Both groups received pharmacological treatment with intranasal fluticasone and allergy immunotherapy during the escalation phase. The control group received a placebo, while the experimental group received EPA capsules: 1340 mg and DHA: 924 mg daily for 2 months. RESULTS: The experimental group included 10 patients (2 men and 8 women), with a mean age of 31.5 ± 15.1 years, while the control group included 12 patients (5 men and 7 women) with a mean age of 27.4 ± 14.3 years (p = 0.56 for age). After the intervention, the median quality of life and nasal symptom scores were also similar between both groups (p = 0.668 and p = 0.920, respectively), with no significant differences. CONCLUSION: Supplementation with high doses of EPA and DHA in patients with persistent allergic rhinitis was safe, but there was no evidence of a reduction in severity or improvement in quality of life compared to the placebo group. Further clinical trials are required to clarify its potential role as an adjunctive strategy.
Armenta-Morales J, Rivero-Yeverino D, López-García AI, Papaqui-Tapia JS, Caballero-López CG, Ríos-López JJ, Pacheco Jiménez YE, Villada-Villada E, Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)
and Gene Polymorphisms Affect Omega-3 and Omega-6 Erythrocyte Fatty Acid Composition and Influence the Association Between Dietary Fatty Acid Intake and Lipid Profile in Brazilian Adults.
Polymorphisms in the and genes influence fatty acid metabolism. However, evidence of gene-diet interactions in population-based studies from Brazil remains limited. The objective of this study was to examine associations between single-nucleotide polymorphisms (SNPs) and erythrocyte fatty acid composition and serum lipid concentrations, as well as to explore potential gene-diet interactions. : Data were analyzed from 294 adults (20-93 years) enrolled in the 2015 ISA-Nutrition study. Erythrocyte fatty acid composition and serum lipids were measured using standard enzymatic methods. Dietary intake was assessed by 24 h recalls, and participants were classified into tertiles according to fatty acid intake. Five SNPs were genotyped; rs174546 and rs174570 were prioritized based on linkage disequilibrium. Associations and interactions were assessed using generalized linear models, adjusting for confounders. : Carriers of the minor alleles for rs174546 and rs174570 had significantly lower erythrocyte levels of long-chain polyunsaturated fatty acids, particularly along the ω-6 pathway, suggesting reduced desaturase activity. The rs174546 TT genotype was associated with higher total, very-low-density lipoprotein cholesterol (VLDL), and non-high-density lipoprotein (non-HDL) cholesterolconcentrations. Higher dietary intakes of docosahexaenoic acid (DHA) or a higher linoleic acid to alpha-linolenic acid ratio(LA/ALA ratio) among these carriers were linked to lower serum lipid levels, indicating gene-diet interactions that attenuate adverse genotype effects. In addition, rs174570 TT carriers showed elevated VLDL concentrations, with a significant dietary interaction observed with the LA/ALA ratio. : and polymorphisms influence fatty acid metabolism and interact with diet to shape lipid profiles. These findings highlight the importance of considering gene-diet interactions in cardiometabolic risk.
Batista LD, Rogero MM, Sarti FM, Costa ML, França JLP, Valentini Neto J, Fisberg RM, Metabolites
Videos (3)
Video Feed
Dec 5, 2014
Eat More Walnuts–The Nut with Omega 3s and Good Fats
Eat More Walnuts Learn what makes walnuts a superfood from nutrition coach Lisa Neilsen in this Howcast video. Walnuts are the next superfood. They're the healthiest nut because they're very high in o...
120 views
YouTube
May 20, 2016
Should Pregnant Vegans Take DHA Supplements?
DHA supplements may be beneficial for vegan mothers and their babies. This video was originally published on NutritionFacts.org and republished with permission. NutritionFacts.org DHA, or docosahexa...
37 views
YouTube
Dec 5, 2014
Eat More Walnuts - The Nut with Omega 3s and Good Fats
Learn what makes walnuts a superfood from nutrition coach Lisa Neilsen in this Howcast video. Walnuts are the next superfood. They're the healthiest nut because they're very high in omega-3s. And omeg...
31 views
